# How to Do Due Diligence on a Healthcare Company's Patents and IP: A Step-by-Step Investor Guide > Patent and IP due diligence is one of the highest-leverage steps a healthcare investor can take before committing capital. This guide walks through exactly where to look, what to verify, and which red flags can quietly destroy a thesis. ## Why Patent and IP Due Diligence Can Make or Break a Healthcare Investment For healthcare companies, intellectual property is often the single largest component of enterprise value. A drug, device, or diagnostic platform with weak, expiring, or contested patents can see its competitive moat disappear overnight. Before you invest, you need to independently verify the scope, strength, and remaining life of every material patent claim, not simply accept what a pitch deck summarizes. The sections below give you a precise, primary-source workflow to do exactly that. ## What Primary Sources Should You Check First? Start with official government databases, not third-party summaries, because summaries frequently lag, omit abandoned continuations, or miss post-grant proceedings. - **USPTO Patent Full-Text Database (patents.google.com and ppubs.uspto.gov):** Search by assignee name, inventor, and application number. Download the full prosecution history (the "file wrapper") for every material patent. The file wrapper reveals claim amendments that may have narrowed protection far below what management describes. - **USPTO Patent Trial and Appeal Board (PTAB) portal (ptab.uspto.gov):** Search for any inter partes review (IPR) or post-grant review (PGR) petitions filed against the company's patents. A pending IPR is a serious red flag that a competitor believes key claims are invalid. - **European Patent Office Espacenet (espacenet.epo.org):** Verify whether international filings exist and in which jurisdictions protection is actually granted. A drug approved globally but patented only in the US has a fundamentally different competitive position. - **World Intellectual Property Organization PATENTSCOPE (patentscope.wipo.int):** Check PCT applications to understand the pipeline of patents that may or may not be granted in the next two to four years. - **FDA Orange Book and Purple Book:** For pharmaceutical and biologic companies, cross-reference listed patents with the company's own claims. If a drug is FDA-approved but its patents are not listed in the Orange Book, competitors face fewer regulatory barriers to entry. ## How Do You Assess Patent Strength and Scope? Filing date and expiration date are table stakes. The harder, more important question is whether the claims are broad enough to block competitors and narrow enough to survive validity challenges. Read the independent claims in each patent. Independent claims define the outer boundary of protection; dependent claims add specificity. A company that only holds patents on narrow formulation variations, not the active molecule or core mechanism of action, has weaker IP than its narrative suggests. Look for claim differentiation from prior art. Search PubMed (pubmed.ncbi.nlm.nih.gov) for publications by the same inventors predating the patent application. Inventor self-publication before the filing date can create prior art complications, particularly for applications with pre-America Invents Act priority dates. Check whether the patents cover the product actually on the market or in late-stage trials. Companies sometimes emphasize patents that protect earlier-generation technology while the commercially relevant product has thinner coverage. ## What Are the Biggest Red Flags in Healthcare IP Due Diligence? - **Patent cliffs without pipeline coverage:** Use the USPTO database to calculate weighted average remaining patent life across the portfolio. If more than half of revenue-generating protection expires within three years and no continuation applications are pending, that is a structural risk. - **Pending PTAB proceedings:** Any active IPR or PGR filing is a sign that sophisticated parties, often generic manufacturers or competitors, have identified potentially invalidating prior art. - **Sole-inventor dependency:** If a single inventor holds all foundational patents and that individual has departed the company, check employment and assignment agreements disclosed in SEC EDGAR filings. Unassigned invention rights are a material liability. - **Licensing agreements with termination triggers:** Search SEC EDGAR (sec.gov/cgi-bin/browse-edgar) for 10-K and 10-Q filings and read IP licensing footnotes carefully. Some in-licensed patents revert to the licensor on bankruptcy, change-of-control, or failure to hit milestones. - **Continuation application gaps:** A company that stopped filing continuation applications three or more years ago is signaling that it has stopped investing in expanding its claim scope, a bearish sign for long-term moat depth. - **Geographic coverage mismatch:** A company targeting global markets but holding patents only in the US and EU may face immediate generic competition in high-growth markets in Asia or Latin America. ## How Do You Verify Ownership and Freedom to Operate? Patent ownership is not always what it appears. Search the USPTO Assignment Database (assignment.uspto.gov) to confirm that all material patents have been formally assigned to the company, not left in the name of a university, a previous employer, or an individual inventor. Freedom to operate (FTO) analysis determines whether the company can commercialize its product without infringing third-party patents. Request or commission a formal FTO opinion from a registered patent attorney. In early-stage deals, absence of a recent FTO opinion is itself a red flag. For later-stage companies, review any litigation history in PACER (pacer.uscourts.gov) for active or resolved infringement suits. ## How Do You Connect IP to Clinical and Regulatory Timeline? Patent strength only creates value if the underlying product reaches commercialization before protection erodes. Cross-reference patent expiration dates with the clinical timeline on ClinicalTrials.gov (clinicaltrials.gov). A Phase 2 drug whose core composition-of-matter patent expires before a plausible Phase 3 completion date has a dramatically compressed commercial window, even if the science is sound. ## Quick IP Due Diligence Checklist - [ ] Downloaded full prosecution history for all material patents from USPTO - [ ] Searched PTAB for active IPR or PGR petitions - [ ] Verified formal patent assignments in USPTO Assignment Database - [ ] Checked Orange Book or Purple Book listings against company claims - [ ] Calculated weighted average remaining patent life across portfolio - [ ] Confirmed geographic coverage matches target markets via Espacenet and PATENTSCOPE - [ ] Reviewed all IP-related footnotes in SEC EDGAR filings - [ ] Searched PubMed for inventor prior publications - [ ] Confirmed freedom-to-operate opinion exists and is recent - [ ] Cross-referenced patent expiration with ClinicalTrials.gov timeline ## How MedFuel Intel Automates This Workflow Working through the above databases manually for a single company can take fifteen to twenty hours and still leave gaps if you miss a continuation application or a recently filed PTAB petition. MedFuel Intel's AI due-diligence platform runs this entire workflow automatically, pulling live data from USPTO, PTAB, SEC EDGAR, ClinicalTrials.gov, and PubMed, flagging patent cliffs, ownership gaps, and litigation risk in a structured report with primary-source citations you can verify yourself. Run a free Red Flag Screener on any healthcare company you are evaluating at https://www.medfuelintel.com and get your first set of IP risk signals in minutes, not weeks. --- *Informational only, not investment advice.* --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/how-to-do-due-diligence-on-a-healthcare-company-s-patents-and-ip). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.